Jove
Visualize
Contact Us

Related Experiment Videos

Non-peptide oxytocin agonists.

Gary R W Pitt1, Andrzej R Batt, Robert M Haigh

  • 1Ferring Research Ltd, Chilworth Science Park, Southampton SO16 7NP, UK.

Bioorganic & Medicinal Chemistry Letters
|September 11, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials.

The World Allergy Organization journal·2026
Same author

Impact of Oral Sebetralstat on Anxiety Associated With Hereditary Angioedema Attacks.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Sebetralstat for On-Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT-S.

Clinical and translational allergy·2025
Same author

Correction to "Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema".

Journal of medicinal chemistry·2025
Same author

Long-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension.

The journal of allergy and clinical immunology. In practice·2025
Same author

Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: A Systematic Review.

Clinical reviews in allergy & immunology·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Researchers developed novel, non-peptide agonists for the oxytocin receptor. These small molecules show potent activity, offering new tools for studying oxytocin (OT) signaling pathways and potential therapeutic applications.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Molecular Biology

Background:

  • The vasopressin/oxytocin receptor family plays crucial roles in physiological processes.
  • Oxytocin (OT) is a key hormone involved in social bonding, reproduction, and stress response.
  • Developing selective and potent modulators of oxytocin receptors is important for research and therapeutic development.

Purpose of the Study:

  • To discover and characterize novel, non-peptide, low molecular weight agonists for the human oxytocin receptor.
  • To identify compounds with optimized potency and selectivity for the oxytocin receptor.

Main Methods:

  • Screening of a compound library against a cloned human oxytocin receptor.
  • Utilizing a reporter gene assay to measure receptor activity.

Related Experiment Videos

  • Optimization of compound potency and selectivity.

    • Main Results:

    • Identification of a series of non-peptide compounds targeting the oxytocin receptor.
    • Compound 39 demonstrated significant potency with an EC50 of 33 nM.
    • This represents the first disclosure of low molecular weight, non-peptide oxytocin agonists.

    Conclusions:

    • The study successfully identified novel non-peptide agonists for the human oxytocin receptor.
    • These compounds provide valuable chemical probes for investigating oxytocin receptor function.
    • The findings open avenues for developing new therapeutic agents targeting oxytocin-mediated pathways.